Avidity Biosciences, Inc. (RNAM)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Avidity Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 187 | $5,716.88 | $13,624.82 | $7,907.94 | 138.33% |
 Kasey Fegan Corsicana & Co. | 8,000 | $348,560 | $582,880 | $234,320 | 67.23% |
 Timothy Tenneriello Oliver Lagore Vanvalin Investment Group | 663 | $15,303.11 | $48,306.18 | $33,003.07 | 215.66% |
 Michael Byun SageView Advisory Group LLC | 45 | $3,247 | $3,210.3 | -$36.7 | -1.13% |
Avidity Biosciences, Inc. (RNAM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Avidity Biosciences, Inc. ever had a stock split?
Avidity Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sarah Boyce CEO | NASDAQ (NMS) Exchange | 05370A108 CUSIP |
| US Country | 511 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Avidity Biosciences, Inc. is a pioneering biotechnology company focused on advancing a new category of therapies known as Antibody Oligonucleotide Conjugates (AOCs). Founded on November 13, 2012, by industry leaders Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick, the company is headquartered in San Diego, California. Avidity is dedicated to addressing the genetic underpinnings of various diseases through innovative solutions that combine the strengths of monoclonal antibodies with oligonucleotide-based treatments.
Leveraging its proprietary AOC platform, Avidity is committed to enhancing therapeutic efficacy by enabling precise targeting of cells and tissues that have been difficult to reach with traditional treatments. The company's approach reflects a significant advancement in the field of biotechnology, with the potential to transform the landscape of therapeutic options available for patients.
Products and Services
- Antibody Oligonucleotide Conjugates (AOCs)
Avidity's flagship product line, AOCs, combines the robust targeting capabilities of monoclonal antibodies with the gene-silencing power of oligonucleotides. This innovative pairing aims to deliver treatment directly to specific cell types, maximizing therapeutic effectiveness while minimizing off-target effects.
- Proprietary AOC Platform
The AOC platform is the technological backbone of Avidity's therapies, allowing the company to engineer bespoke therapies tailored to the genetic profile of various diseases. This platform is designed to optimize the pharmacokinetics and therapeutic indices of the AOCs, ensuring enhanced delivery and action at the cellular level.
- Preclinical and Clinical Development Programs
Avidity conducts extensive research and development programs aimed at testing the safety and efficacy of its AOCs. These programs include preclinical studies and phases of clinical trials designed to validate the therapeutic potential of AOCs against a variety of genetic disorders.
- Collaborative Partnerships
Through strategic partnerships with other biotech firms, academic institutions, and research entities, Avidity seeks to accelerate its research efforts and expand its capabilities. Collaborations enhance the company's ability to innovate and explore new therapeutic avenues.
- Regulatory and Compliance Services
Avidity provides comprehensive regulatory support to navigate the complexities of bringing new therapies to market. This includes preparing submissions for Investigational New Drug (IND) applications and maintaining compliance with regulatory standards throughout the development process.
